A study on the concentrations of levofloxacin in the gallbladder tissue and bile of patients
Abstract
Concentrations of levofloxacin (LVFX, DR-3355), optically active (-)-ofloxacin, in the gall-bladder tissue and bile were determined in patients, and the results were as follows: 1. A single dose of LVFX (100 mg) was administered orally to 6 patients with cholelithiasis about 2 to 3 hours before operation. The range in the gallbladder tissues was 0.34 to 1.59 micrograms/g, while the range in sera was 0.20 to 1.05 micrograms/ml. The ranges in the adipose tissues, gallbladder bile, and common duct bile were 0.07 to 0.26 micrograms/g, 1.8 to 12.2 micrograms/ml, and 1.4 to 5.8 micrograms/ml, respectively. 2. A single dose of LVFX (100 mg) was administered orally to 5 patients with indwelling T-tube. Concentrations of LVFX in excreted bile samples were 1.2 to 2.4 micrograms/ml, 1.3 to 3.5 micrograms/ml, and 1.3 to 2.4 micrograms/ml at 2 to 4, 4 to 6, and 6 to 12 hours after administration, respectively. Therefore, it appears that LVFX may be effective in biliary tract infections, because of its sustained high concentrations in biliary system.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.